Letzte Zahlen 21. Juli 2026
Novartis AG ADR
I · KI-Analyse
Kurzfassung
Novartis develops and sells prescription medicines across cardiovascular disease (Entresto for heart failure), immunology (Cosentyx for psoriasis and arthritis), oncology (Pluvicto for prostate cancer, Kisqali for breast cancer), and rare diseases (Zolgensma for spinal muscular atrophy) [Yahoo Finance]. The company operates globally, manufacturing drugs in multiple countries and selling through hospitals, clinics, and specialty pharmacies [Yahoo Finance].
Novartis is a Swiss pharmaceutical giant with over 75.000 employees making drugs for heart disease, cancer, immune disorders, and rare genetic conditions [Yahoo Finance]. The company posted $54,8B in revenue with strong margins (75% gross, 32% operating) and solid cash generation ($17,7B free cash flow), reflecting a diversified portfolio of branded medicines [Yahoo Finance]. Recent positive clinical trial results for Pluvicto, a radioactive cancer therapy, have driven modest stock gains and positioned Novartis as a leader in an emerging treatment category [Simply Wall St].
Novartis is financially healthy with strong profitability, low leverage, and consistent cash generation [Yahoo Finance].
Sentinellis-Score
8,9/10
Finanziell gesund
Marktkapitalisierung
$287,1B
Umsatz (12 Monate)
$54,8B
Erklärt
Wie wir diese Zahlen lesen
Verständliche Leitfäden · ohne Konto
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
LesenPiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
LesenAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
LesenII · Aktuelle Nachrichten
Was den Kurs bewegt hat
6 Meldungen · nach Relevanz sortiert
- Makro2026-05-20
Novartis (SWX:NOVN) Valuation Check After New Pluvicto PSMAddition Study Data And Regulatory Filings
Simply Wall St
- Makro2026-05-18
Hepatic Cirrhosis Market Research and Forecast Report 2026-2036, Profiles of Abbott, Astellas Pharma, Gilead Sciences, Novartis, Takeda Pharma, Grifols Therapeutics, and Cellaion
Yahoo Finance
- Makro2026-05-18
Novartis' Pluvicto Shows Lower Risk Of PSA Progression In Phase 3 PSMAddition Trial For MHSPC
Nasdaq
- Makro2026-05-14
Novartis Expands US Radioligand Network And Manufacturing For Future Growth
Simply Wall St
- Makro2026-05-17
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
Yahoo Finance
- Makro2026-05-14
Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Antagonists and Inhibitors by Drug Modality
Yahoo Finance
Premium · kostenlos mit jedem Konto
Patent expirations on blockbuster drugs will eventually erode revenue unless the pipeline delivers replacements — a structural risk in pharmaceutical business models [Yahoo Finance]
Risiken
4
Chancen
5
Warnsignale
2
Führung
10
10 weitere Erkenntnisse im vollständigen Bericht — kostenlos mit jedem Konto.
Vollständige Novartis AG ADR-Analyse freischalten
Erstellen Sie ein kostenloses Konto für den vollständigen KI-Bericht mit Quellenangaben im Text.
- 4 Risiken, 5 Chancen und 2 Warnsignale — jeweils mit Quelle
- Über 100 Finanzkennzahlen mit Charts und Vergleichen
- Vollständige Nachrichten-Zusammenfassungen mit Quellenlinks
- Führungsteam und Vergütung
III · Ähnliche Unternehmen
Das könnte Sie auch interessieren
Gleicher Sektor · Gesundheitswesen — oder vergleichbare Finanzlage
Auf Ihre Watchlist setzen?